Cardiac biomarkers for diagnosis have become more sensitive in recent decades.Load more
Cardiac biomarkers for diagnosis have become more sensitive in recent decades.
Cardiac troponin is the preferred biomarker for the diagnosis of MI, and considerable efforts have been invested in the development and implementation of high-sensitivity cardiac troponin (hs-cTn) assays.
The currently used hs-cTn assays are highly valuable and their use is outlined by international guidelines. Acute changes in hs-cTn complement the quantitative information provided by hs-cTn, and help in the differential diagnosis of diseases with chronic, stable troponin elevations versus diseases with acute troponin elevations and acute cardiac damage.Load Less
Hans-Peter Brunner-La Rocca, Sandra Sanders-van WijkCardiac Failure Review 2019;5(1):44–9.DOI: https://doi.org/10.15420/cfr.2018.26.1
Mohammad S Alzahri, Anita Rohra , W Frank Peacock, et alCardiac Failure Review 2016;2(1):51–5DOI: https://doi.org/10.15420/cfr.2016:3:3
Current Understanding of the Compensatory Actions of Cardiac Natriuretic Peptides in Cardiac Failure: A Clinical PerspectiveNoel S Lee, Lori B DanielsCardiac Failure Review 2016;2(1):14–9DOI: https://doi.org/10.15420/cfr.2016:4:2
Francesco Orso, Gianna Fabbri, Aldo Pietro Maggioni, et alArrhythmia & Electrophysiology Review 2015;4(3):163–8DOI: https://doi.org/10.15420/aer.2015.4.3.163